Oncology Research2026，Vol.34Issue(9)：P.281-314,34.DOI:10.32604/or.2026.083902
Nuclear-Cytoplasmic Axis in Cancer:From Protein Mislocalization to Anticancer Drug Resistance
Xueping Zhu 1Misi He 1Ling Wang 1Rui Su 2Lin Zhong 1Ting Guo 3Haixia Wang 1Dongling Zou1
作者信息
- 1. Department of Gynecologic Oncology,Chongqing University Cancer Hospital,Chongqing Cancer Institute,Chongqing Cancer Hospital,Chongqing,China Chongqing Specialized Medical Research Center of Ovarian Cancer,Chongqing,China Organoid Transformational Research Center,Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital,Chongqing,China
- 2. Department of Systems Biology,Beckman Research Institute of City of Hope,Monrovia,CA,USA
- 3. Department of Gynecologic Oncology,Chongqing University Cancer Hospital,Chongqing Cancer Institute,Chongqing Cancer Hospital,Chongqing,China Chongqing Specialized Medical Research Center of Ovarian Cancer,Chongqing,China Organoid Transformational Research Center,Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital,Chongqing,China Department of Systems Biology,Beckman Research Institute of City of Hope,Monrovia,CA,USA
- 折叠
摘要
关键词
Nucleocytoplasmic transport/nuclear pore complex/transport receptors/anticancer drug resistance/post-translational modifications/tumor microenvironment/nuclear localization signal mutations/nuclear export signal mutations分类
医药卫生引用本文复制引用
Xueping Zhu,Misi He,Ling Wang,Rui Su,Lin Zhong,Ting Guo,Haixia Wang,Dongling Zou..Nuclear-Cytoplasmic Axis in Cancer:From Protein Mislocalization to Anticancer Drug Resistance[J].Oncology Research,2026,34(9):P.281-314,34.基金项目
supported by the Talent Program of Chongqing(Grant No.cstc2024rcihbgzxm0162 to Dongling Zou and YXGD202403 to Haixia Wang). （Grant No.cstc2024rcihbgzxm0162 to Dongling Zou and YXGD202403 to Haixia Wang）
